EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Engineered Cas9 variants bypass Keap1-mediated degradation in human cells and enhance epigenome editing efficiency

Jianfeng Chen, Siyuan Su, Adrian Pickar-Oliver, Anna M Chiarella, Quentin Hahn, Dennis Goldfarb, Erica W Cloer, George W Small, Smaran Sivashankar, Dale A Ramsden, Michael B Major, Nathaniel A Hathaway und 2 weitere

Nucleic Acids Research · 2024

DOI: 10.1093/nar/gkae761 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, 2024. Verfasst von Jianfeng Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Hauptthemen laut MEDLINE: Kelch-Like ECH-Associated Protein 1, Gene Editing, CRISPR-Cas Systems, CRISPR-Associated Protein 9. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIBIB NIH HHS, Pfizer-NCBiotech Distinguished Postdoctoral Fellowship, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a potent and convenient genome-editing tool, Cas9 has been widely used in biomedical research and evaluated in treating human diseases. Numerous engineered variants of Cas9, dCas9 and other related prokaryotic endonucleases have been identified. However, as these bacterial enzymes are not naturally present in mammalian cells, whether and how bacterial Cas9 proteins are recognized and regulated by mammalian hosts remain poorly understood. Here, we identify Keap1 as a mammalian endogenous E3 ligase that targets Cas9/dCas9/Fanzor for ubiquitination and degradation in an ‘ETGE’-like degron-dependent manner. Cas9-‘ETGE’-like degron mutants evading Keap1 recognition display enhanced gene editing ability in cells. dCas9-‘ETGE’-like degron mutants exert extended protein half-life and protein retention on chromatin, leading to improved CRISPRa and CRISPRi efficacy. Moreover, Cas9 binding to Keap1 also impairs Keap1 function by competing with Keap1 substrates or binding partners for Keap1 binding, while engineered Cas9 mutants show less perturbation of Keap1 biology. Thus, our study reveals a mammalian specific Cas9 regulation and provides new Cas9 designs not only with enhanced gene regulatory capacity but also with minimal effects on disrupting endogenous Keap1 signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kelch-Like ECH-Associated Protein 1Gene EditingCRISPR-Cas SystemsCRISPR-Associated Protein 9UbiquitinationHumansHEK293 CellsEpigenomeProteolysisUbiquitin-Protein LigasesProtein EngineeringChromatin

Substanzen

Kelch-Like ECH-Associated Protein 1KEAP1 protein, humanCRISPR-Associated Protein 9Ubiquitin-Protein LigasesChromatin

Autor:innen und Institutionen

  • Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Department of Biochemistry and Biophysics, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Department of Biomedical Engineering, Duke University, Durham, NC 27710, USA.
  • Center for Advanced Genomic Technologies, Duke University, Durham, NC 27710, USA.
  • Division of Chemical Biology and Medicinal Chemistry, Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, The University of North Carolina, Chapel Hill, NC 27599, USA.
  • Curriculum in Genetics and Molecular Biology, The University of North Carolina, Chapel Hill, NC 27599, USA.

ORCID-Profile: Pengda Liu

Förderung

  • NIBIB NIH HHS
  • Pfizer-NCBiotech Distinguished Postdoctoral Fellowship
  • NCI NIH HHS
  • NIAMS NIH HHS
  • NIGMS NIH HHS
  • NIH HHS
  • UNC Lineberger Comprehensive Cancer Center Development Award
  • UNC University Cancer Research Fund

Zitieren

APA

Chen, J., Su, S., Pickar-Oliver, A., Chiarella, A. M., Hahn, Q., Goldfarb, D., Cloer, E. W., Small, G. W., Sivashankar, S., Ramsden, D. A., Major, M. B., Hathaway, N. A., Gersbach, C. A., & Liu, P. (2024). Engineered Cas9 variants bypass Keap1-mediated degradation in human cells and enhance epigenome editing efficiency. Nucleic Acids Research. https://doi.org/10.1093/nar/gkae761

Vancouver

Chen J, Su S, Pickar-Oliver A, Chiarella AM, Hahn Q, Goldfarb D, et al. Engineered Cas9 variants bypass Keap1-mediated degradation in human cells and enhance epigenome editing efficiency. Nucleic Acids Research. 2024. doi:10.1093/nar/gkae761

BibTeX
@article{Chen2024,
  author = {Chen, Jianfeng and Su, Siyuan and Pickar-Oliver, Adrian and Chiarella, Anna M and Hahn, Quentin and Goldfarb, Dennis and Cloer, Erica W and Small, George W and Sivashankar, Smaran and Ramsden, Dale A and Major, Michael B and Hathaway, Nathaniel A and Gersbach, Charles A and Liu, Pengda},
  title = {Engineered Cas9 variants bypass Keap1-mediated degradation in human cells and enhance epigenome editing efficiency},
  journal = {Nucleic Acids Research},
  year = {2024},
  doi = {10.1093/nar/gkae761}
}
Kostenlos starten →